Treatment of acute renal failure with urodilatin after unrelated bone marrow transplantation in an 18-month-old boy.
Acute renal failure was imminent in an 18-month-old male infant 20 days after unrelated BMT. The infant was treated with urodilatin (URO), a natriuretic vasorelaxant peptide. Diuresis increased 2 h after the commencement of URO infusion and the furosemide infusion was reduced from 5 mg/h to 2.5 mg/h. After seven days of URO treatment diuresis was normal, the serum creatinine level had decreased, and furosemide was reduced from 12 mg/kg bw/d to 1.8 mg/kg bw/d. No side effects were observed either during or following URO therapy. We consider URO to be a promising drug for the treatment, without any apparent side effects, of imminent or manifest acute renal failure in infants following BMT.